Table 1.
Characterization of Control Patients
| Patient Number | Sex | Age | Diagnosis | Duration of Diabetes | Previous PRP | TSP1 | PEDF |
|---|---|---|---|---|---|---|---|
| 1 | F | 73 | MH | NA | No | +++ | ++++(H) |
| 2 | M | 64 | ERM | NA | No | +++ | ++++(H) |
| 3 | F | 72 | ERM | NA | No | +++ | ++++(H) |
| 4 | F | 54 | MH | NA | No | ++++ | ++++(L) |
| 5 | M | 71 | ERM | NA | No | ++++ | ++++(L) |
| 6 | F | 61 | ERM | NA | No | ++ | ++++(H) |
| 7 | F | 76 | ERM | NA | No | +++ | ++++(L) |
| 8 | M | 78 | ERM | NA | No | +++ | ++++(L) |
| 9 | M | 72 | ERM | NA | No | +++ | ++++(H) |
| 10 | M | 76 | ERM | NA | No | +++ | ++++(L) |
| 11 | F | 75 | ERM | NA | No | +++ | ++++(H) |
| 12 | F | 87 | ERM | NA | No | +++ | ++++(H) |
| 13 | M | 65 | ERM | NA | No | ++++ | ++++(L) |
| 14 | F | 60 | MH | NA | No | ++++ | ++++(L) |
| 15 | M | 77 | MH | NA | No | ++++ | ++++(L) |
| 16 | M | 72 | MH | NA | No | ++++ | ++++(L) |
| 17 | F | 65 | MH | NA | No | +++ | ++++(H) |
| 18 | M | 72 | MH | NA | No | +++ | ++++(L) |
| 19 | F | 60 | MH | NA | No | ++++ | ++++(L) |
| 20 | F | 63 | MH | NA | No | ++++ | ++++(L) |
| 21 | F | 71 | MH | NA | No | ++++ | ++++(H) |
MH: Macular Hole
ERM: Epiretinal Membrane
NA: Not Applicable
H: Higher Molecular Weight PEDF
L: Lower Molecular Weight PEDF
PRP: Panretinal photocoagulation